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Some new and important concepts have emerged from the research of the last five years
about quinolones in general and pefloxacin, in particular. These can be summarized as
follows.
Microbiological aspects
The quinolones in general, and pefloxacin in particular, have minimal bactericidal
concentrations (MBQ that are close to their minimal inhibitory concentrations (MIC).
They all exert a strong postantibiotic effect, are active to some extent on resting
bacteria and show a paradoxical decrease in activity if used at very high concentrations,
or in the presence of protein inhibitors. Development of resistance has become well
documented, mostly in Staphylococcus aweus and Pseudomonas aeruginosa, less often
in other bacteria such as the Enterobacteriaceae. The development of resistance in
5. aureus and P. aeruginosa is of some concern when quinolones are used for the
long-standing treatment of osteomyelitis, and of lung infections in patients with cystic
fibrosis.
Biological properties
Subinhibitory concentrations of pefloxacin have been shown to decrease the adherence
of Gram-negative bacteria to intestinal cells, and of Gram-positive bacteria (5. aweus)
to buccal cells. A decrease in adherence after treatment with sub-MIC concentrations
has also been demonstrated with Escherichia coli on uroepithelial cells, and with
Enterococcus faecalis to a platelet fibrin matrix. Uptake of pefloxacin, with higher
intracellular than extracellular concentrations at 120 min (ratio up to 8) has been
shown for macrophages, polymorphonuclear leucocytes and fibroblasts. Pefloxacin
seems to concentrate in the cytoplasm. Release of pefloxacin with outward movement
from the cell also occurs, and is influenced by the degree of activation of the
macrophage; the intracellular concentration of pefloxacin therefore depends on these
two mechanisms: penetration and extrusion.
Pharmacology and toxicology
In order to ensure safety, although the maximum tolerated plasma concentrations have
not been clearly defined, the dosage of all quinolones should be reduced in renal failure
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(creatinine clearance below 10 ml/min) with doubling of the interval between doses
except in the case of pefloxacin. All the quinolones are poorly removed by
haemodialysis, and therefore no change in the regimen is required under such
conditions. Liver failure also influences the pharmacokinetics of the quinolones, but
most of the pharmacokinetic data have been obtained in cirrhotic patients, who
unfortunately are not equivalent to patients with impaired hepatocellular or
hepatosecretory functions.
Review of the clinical studies has shown a 2-3-3-8% incidence of side effects. Of
greatest clinical importance are certainly the effects on the central nervous system,
which were found in 0-9% of patients. One of these side effects has been quite well
delineated, and involves convulsions under well-defined clinical or experimental
conditions.
Thus, fenbufen and enoxacin given together have led occasionally to seizures in man,
whereas fenbufen and any quinolone may lead to convulsions in animals. Other
side effects of minor importance to be considered are arthralgia, and
thrombocytopenia; the latter has occurred in association with heparin treatment, and it
is still difficult to define which of the two drugs is the major culprit in inducing this
effect.
Clinical aspects
Some important new clinical successes have to be stressed. Encouraging results are
now being reported with pefloxacin in the long term treatment of chronic osteomyelitis,
although most of the cases reported also involved concomitant surgery. In typhoid
fever, a 7-day course of pefloxacin seems to be highly efficacious. Interesting results
have been obtained with pefloxacin in bacteraemia and meningitis, with a loading dose
of 800 mg. Since reported side effects have so far been neither dose- nor time-related,
this high dosage seems to deserve further investigation as an effective means to treat
life-threatening infections. Interesting results have also been obtained with pefloxacin,
either as single therapy or in combination therapy, in pulmonary infections by
Legionella spp. Single-dose pefloxacin administered in lower urinary tract infections
seems to give in the long run fewer recurrences than treatment with a single dose of a
/Mactam antibiotic, possibly because of the longer half-life and/or the postantibiotic
effect of the quinolone.
The future
Although the last years of investigation have helped to define better many features of
pefloxacin therapy, several aspects of quinolone treatment deserve further
investigations. Non-absorbable quinolones, which would be used only for
gastrointestinal decontamination (neutropenic patients, intensive care unit patients),
would be an interesting adjunct to our present armamentarium. Increased activity
against streptococci, S. aureus, and other Gram-positive bacteria, is being achieved
now with some of the newer quinolones such as temafloxacin and sparfloxacin . These
studies deserve further development. Compounds with a narrow spectrum, but
increased activity against anaerobes, would be of help in gastrointestinal infections. A
better understanding of the non-antimicrobial effects of the quinolones (effects on
adherence, phagocyte interaction, intracellular penetration) may help to define better
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their usage as prophylactic and therapeutic agents. The possibility of administering
high dosages of pefloxacin in indications such as bacteraemia and meningitis has to be
further investigated in detail. The investigations that we are able to review at the
present time may represent only the beginning of the therapeutic potential of the
quinolones.
